U.S. Advanced Therapy Medicinal Products CDMO Market Size, Share & Trends Analysis Report By Product (Gene Therapy, Cell Therapy), By Phase, By Indication,- Industry Analysis, Size, Share, Growth, Trends, and Forecast 2024-2033

U.S. Advanced Therapy Medicinal Products CDMO Market Size and Trends

The U.S. advanced therapy medicinal products CDMO market size was exhibited at USD 2.65 billion in 2023 and is projected to hit around USD 14.24 billion by 2033, growing at a CAGR of 18.31% during the forecast period 2024 to 2033.

U.S. Advanced Therapy Medicinal Products CDMO Market Key Takeaways:

• Gene therapy led the market in 2023 with 49.09% of the total revenue share.
• Cell therapy is expected to grow at the fastest rate from 2024 to 2033.
• In 2023, Phase I clinical trials dominated the market with revenue share of 50.65%.
• Phase III trials are anticipated to grow at the highest CAGR over the forecast period.
• Oncology held the largest revenue share of 45% in 2023.
• The cardiology segment is anticipated to grow lucratively from 2024 to 2033.

Report Scope of U.S. Advanced Therapy Medicinal Products CDMO Market

Key drivers behind this growth include the increasing incidence of rare and severe diseases, significant investments in ATMP R&D, and expanding trend of outsourcing. The complexity of manufacturing ATMPs and growing need for specialized expertise and advanced technologies have fueled the demand for CDMO services, which play a vital role in facilitating the development and commercialization of innovative therapies, thus contributing to market growth.

The U.S. advanced therapy medicinal products CDMO market held the largest share of over 40% of the global advanced therapy medicinal products CDMO market in 2023. Driving factors include a rising number of ATMP clinical trials, growing adoption of advanced therapies, and increasing outsourcing activities. Innovation in technology and manufacturing capabilities by biotech companies create commercial opportunities for market expansion. Recent product approvals have accelerated R&D activities in this field. In addition, a consistent supply of funds and grants has led to the proliferation of ATMP clinical trials. Noncommercial entities, such as universities, sponsor ongoing trials to accelerate their progress.

Outsourcing activities in the ATMP domain are on the rise, as it enables companies to acquire additional competencies for successful development and commercialization of ATMPs. Outsourcing offers extended expertise, better management of cash flows, and significant manufacturing advantages like risk reduction. The low incidence-to-prevalence ratio for genetic and rare diseases makes outsourcing a favorable alternative. In-house facility construction for single gene therapies requires fast cost recovery, and outsourcing serves as an effective strategy until market demand is established. Limited understanding of final scale requirements for current and future products also supports outsourcing preferences.

Public awareness about ATMP treatment options is increasing due to initiatives aimed at informing people about their benefits. This, in turn, is leading to increased adoption of advanced therapies and fueling market growth for CDMOs. For example, OVID Health launched the Cell and Gene Collective in May 2021 with support from companies like Astellas, bluebird bio, Kite, Bristol Myers Squibb, and Novartis, aiming to raise awareness about cell and gene therapies.

U.S. Advanced Therapy Medicinal Products CDMO Market By Product Insights

Gene therapy led the market in 2023 with 49.19% of the total revenue share, driven by increased financial support, clinical trials, and expected commercialization of these products. Early-stage companies facing challenges in generating in-house capabilities are expected to fuel the demand for CDMO services, contributing to the segment’s growth. Collaborative efforts for novel gene therapy development and expanding applications are expected to boost manufacturing prospects in this domain.

Cell therapy is expected to grow at the fastest rate from 2024 to 2033 due to constant advancements in cellular therapeutics, incorporating new cell types. This provides ample opportunities for companies to strengthen their market positions. The market attracts new entrants because of unmet demand for cell therapy manufacturing, recent approvals of advanced therapies, and proven effectiveness of these products. For example, in October 2022, Lonza‘s Houston site received FDA approval for two cell and gene therapies, ZYNTEGLO and SKYSONA, both developed by bluebird bio. This marks the third commercial cell and gene therapy product supported by Lonza’s facility, showcasing the effectiveness of its New Product Introduction process.

U.S. Advanced Therapy Medicinal Products CDMO Market By Phase Insights

In 2023, Phase I clinical trials dominated the market with revenue share of 50.65%. These trials were primarily focused on establishing the maximum tolerated dose for patients without adverse effects. Approximately 70% of Phase I drug candidates progress to the next phase. The increasing number of preclinical studies and involvement of small and startup biotechnology and biopharmaceutical companies in R&D activities have led to a rise in demand for CDMOs to conduct Phase I clinical trials. Due to the complex and costly nature of new drug development, companies are outsourcing CDMO services to initiate clinical studies. As emerging biotechnology firms require CDMOs to conduct early-phase trials according to their study requirements, this trend is expected to drive market growth.

Phase III trials are anticipated to grow at the highest CAGR over the forecast period. Phase 3 trials involve a large number of patients and represent the most extensive study period, as they focus on comparing the efficiency and safety of a new drug. An average Phase 3 trial typically lasts between 1 to 4 years. The significant involvement of patients in Phase 3 clinical trials leads to a high demand for therapeutic products required for conducting these studies, thereby increasing the segment growth. This growth is driven by the need for comprehensive evaluation and validation of new drugs before they can be approved and marketed.

U.S. Advanced Therapy Medicinal Products CDMO Market By Indication Insights

Oncology held the largest revenue share of 45% in 2023 and is anticipated to register the fastest growth over the forecast period. The high number of cancer cases has increased the need for advanced treatments, leading to a big demand for manufacturing services in oncology. Competition among key companies and new treatments have made oncology even more important. As of January 2021, about 18,000 to 19,000 patients could benefit from cell and gene therapies like Kymriah (Novartis AG) and Yescarta (Gilead Sciences, Inc.) for cancer treatment.

The cardiology segment is anticipated to grow lucratively from 2024 to 2033, to the rising prevalence of cardiovascular diseases and collaborative research efforts aimed at developing advanced therapies. Cardiovascular diseases (CVDs) stand as the primary cause of mortality in the U.S., with heart disease being the leading contributor. Despite notable progress in prevention, diagnosis, and treatment, CVDs persist as a substantial health concern. The considerable mortality rate underscores the urgent requirement for innovative treatments to alleviate the burden of these diseases.

U.S. Advanced Therapy Medicinal Products CDMO Market Recent Developments

• In February 2024, Thermo Fisher Scientific expanded its biologics manufacturing facility in St. Louis, Missouri, U.S., doubling its capacity to produce complex treatments for various diseases. This expansion made the facility the largest single-use technology CDMO in the country.
• In February 2023, Lonza, a global manufacturing partner for the pharmaceutical, biotech, and nutrition industries, announced its plans to expand Early Development Services (EDS) into Cambridge, Massachusetts (U.S.), North America.
• In February 2022, AGC Biologics entered into a supply agreement with Pfizer, Inc. for the supply of plasmid DNA used for development of an Omicron-based vaccine candidate. The first batch of the vaccine was scheduled to be available by the end of March 2022, according to the company.
• In February 2022, Thermo Fisher Scientific, Inc. announced the launch of new integrated commercial packaging and distribution services aimed to help patients in the U.S. and Europe transition from clinic to commercial launch.
• In June 2021, Dendreon Pharmaceuticals, a biopharmaceutical manufacturer of cell therapies, shifted into the CDMO business for late-stage cell therapies to address expertise gaps and rising demand for end-to-end manufacturing.

Some of the prominent players in the U.S. advanced therapy medicinal products CDMO market include:

• Celonic
• Bio Elpida
• CGT Catapult
• Rentschler Biopharma SE
• AGC Biologics
• Catalent
• Lonza
• WuXi Advanced Therapies
• BlueReg
• Minaris Regenerative Medicine
• Patheon

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. advanced therapy medicinal products CDMO market

Product

• Gene Therapy
• Cell Therapy
• Tissue Engineered
• Other Products

Phase

• Phase I
• Phase II
• Phase III
• Phase IV

Indication

• Oncology
• Cardiology
• Central Nervous System
• Musculoskeletal
• Infectious Disease
• Dermatology
• Endocrine, Metabolic, Genetic
• Immunology & Inflammation
• Opthalmology
• Haematology
• Gasteroenterology
• Other Indications